2026-2034年全球急性偏頭痛治療市場規模、佔有率、趨勢和成長分析報告

預計到 2034 年，急性偏頭痛治療市場規模將從 2025 年的 48 億美元成長至 176.4 億美元，2026 年至 2034 年的複合年成長率為 15.57%。

受全球偏頭痛盛行率上升的推動，全球急性偏頭痛治療市場正經歷強勁成長。壓力水平的增加、生活方式的改變以及人們對神經系統健康意識提升，都促使偏頭痛的診斷率不斷上升。對起效迅速、療效顯著的治療方法（包括曲坦類藥物和CGRP拮抗劑）的需求日益成長。藥物技術的進步以及對偏頭痛病理生理學更深入的理解，進一步加速了市場的發展。

關鍵成長要素包括醫療保健覆蓋範圍的擴大、神經系統研究投入的增加以及新療法的推出。慢性偏頭痛在工作年齡人口中日益嚴重的負擔推動了對先進治療方案的需求。此外，患者對非侵入性和標靶治療的偏好也促進了產品創新。新一代藥物監管核准的增加和宣傳宣傳活動也有助於提高全球藥物普及率。

受持續藥物研發和生物製藥療法拓展的推動，市場前景依然強勁。個人化醫療方法和數位化健康監測工具可望提升治療效果。新興市場醫療保險覆蓋範圍的擴大將開闢新的成長路徑。持續的研發投入和產品線創新預計將推動急性偏頭痛治療市場實現長期持續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球急性偏頭痛治療市場：依藥物類型分類

• 市場分析、洞察與預測
• 曲坦類藥物
• CGRP拮抗劑
• 非類固醇消炎劑（NSAIDs）
• BETA阻斷劑
• 麥角生物鹼
• 其他

第5章：全球急性偏頭痛治療市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 注射
• 其他

第6章：全球急性偏頭痛治療市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球急性偏頭痛治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Teva Pharmaceutical
  • Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Amgen
  • AstraZeneca
  • Pfizer Inc
  • Merck & Co
  • Novartis AG
  • Allergan Plc
  • Eli Lilly And Company
  • BioDelivery Sciences International Inc
  • AbbVie

The Acute Migraine Treatment Market size is expected to reach USD 17.64 Billion in 2034 from USD 4.80 Billion (2025) growing at a CAGR of 15.57% during 2026-2034.

The Global Acute Migraine Treatment Market is witnessing robust growth driven by rising prevalence of migraine disorders worldwide. Increasing stress levels, lifestyle changes, and neurological health awareness are contributing to higher diagnosis rates. Demand for fast-acting and effective treatment options, including triptans and CGRP antagonists, is expanding. Pharmaceutical advancements and improved understanding of migraine pathophysiology are further accelerating market development.

Key growth drivers include increasing healthcare access, rising investment in neurological research, and the introduction of novel therapeutics. The growing burden of chronic migraine among working-age populations is encouraging demand for advanced treatment solutions. Additionally, patient preference for non-invasive and targeted therapies is shaping product innovation. Regulatory approvals of next-generation drugs and increasing awareness campaigns are also boosting adoption rates globally.

Future prospects remain strong with continued drug development and expansion of biologic therapies. Personalized medicine approaches and digital health monitoring tools are expected to enhance treatment outcomes. Expanding healthcare coverage in emerging markets will create new growth avenues. With ongoing research and pipeline innovations, the acute migraine treatment market is poised for sustained long-term expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• Triptans
• CGRP Antagonist
• NSAID Drugs
• Beta-Adrenergic Blockers
• Ergot Alkaloids
• Others

By Route of Administration

• Oral
• Injection
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Teva Pharmaceutical, HoffmannLa Roche Ltd, Johnson Johnson, Amgen, AstraZeneca, Pfizer Inc, Merck Co, Novartis AG, Allergan Plc, Eli Lilly and Company, BioDelivery Sciences International Inc, AbbVie
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ACUTE MIGRAINE TREATMENT MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Triptans Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. CGRP Antagonist Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. NSAID Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Beta-Adrenergic Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Ergot Alkaloids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ACUTE MIGRAINE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ACUTE MIGRAINE TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ACUTE MIGRAINE TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Type
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Type
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Type
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Type
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Type
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ACUTE MIGRAINE TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Teva Pharmaceutical
  • 9.2.2 Hoffmann-La Roche Ltd
  • 9.2.3 Johnson & Johnson
  • 9.2.4 Amgen
  • 9.2.5 AstraZeneca
  • 9.2.6 Pfizer Inc
  • 9.2.7 Merck & Co
  • 9.2.8 Novartis AG
  • 9.2.9 Allergan Plc
  • 9.2.10 Eli Lilly And Company
  • 9.2.11 BioDelivery Sciences International Inc
  • 9.2.12 AbbVie